ERBB2 and breast carcinoma: Similar to the BOLERO‐2 trial, an international multicenter trial, a significantly prolonged PFS (median PFS: 7.4 months) was observed in the BOLERO‐5 trial, further supporting the application of everolimus and exemestane combination therapy in postmenopausal patients with ER‐positive/HER2‐negative advanced breast cancer in China (Table 2).